Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Regeneron's COVID-19 antibodies breach a new frontier by cutting deaths in some hospitalized patients
Amazon kicks off new role as diagnostics provider by making COVID test available online
70% of employers say they won't mandate COVID vaccinations: Willis Towers Watson
NIH antibody study suggests COVID-19 spread across U.S. earlier than originally known
CDC's new guidance for treating COVID-19 long-haulers warns against relying on labs, imaging results alone
While mRNA saved the COVID-19 day, GSK and Sanofi vaccines likely safe beyond pandemic: analysts
Evotec wants to prevent the next COVID-19 crisis, and you could help
COVID-19 tracker: Russia's Sputnik V authorization delayed in EU; Delta variant cases 'rapidly increasing' in U.S.
BIO 2021: After COVID-19 showcased the power of science, J&J exec urges industry to start thinking 'cure' in cancer
Molecular Partners prices $64M IPO, falling short of original goal

Featured Story

Regeneron's COVID-19 antibodies breach a new frontier by cutting deaths in some hospitalized patients

By Kevin Dunleavy

Hospitalized COVID-19 patients that haven't been able to generate their own antibody responses can benefit from Regeneron's antibody cocktail, a large new study found. The data could take REGEN-COV to a new group of patients—and a new source of sales.

Amazon kicks off new role as diagnostics provider by making COVID test available online

By Andrea Park

Amazon has already changed the way we shop and filled our homes with “smart” gadgets, and now, the tech giant is looking to revolutionize the way we manage our health.

70% of employers say they won't mandate COVID vaccinations: Willis Towers Watson

By Paige Minemyer

Employers are mulling vaccine requirements for certain workplace amenities, such as gyms and cafeterias, a new survey shows.

NIH antibody study suggests COVID-19 spread across U.S. earlier than originally known

By Andrea Park

Though the first confirmed domestic case of COVID-19 was announced Jan. 21, 2020, new research from the NIH indicates that the coronavirus made its way to the U.S. shores well before that—at least as early as December 2019—reaching far beyond the initial hotspots of Washington state and New York.

CDC's new guidance for treating COVID-19 long-haulers warns against relying on labs, imaging results alone

By Dave Muoio

The guidance outlines the "broad spectrum" of symptoms these patients face after acute infection and advocates for patient-centered care approaches targeting quality of life and function.

While mRNA saved the COVID-19 day, GSK and Sanofi vaccines likely safe beyond pandemic: analysts

By Noah Higgins-Dunn

Although the mRNA vaccines from Pfizer-BioNTech and Moderna have shown "astonishing" efficacy against COVID-19, the novel technology is "not a panacea" for other diseases, Jefferies analysts said in a note. That's good news for other vaccine developers, namely Sanofi and GlaxoSmithKline, they argue.

Evotec wants to prevent the next COVID-19 crisis, and you could help

By Kyle LaHucik

German biotech-CRO hybrid Evotec is launching a new program linking up resources across the antiviral therapeutics development chain to fight the “permanent global threat" of a pandemic.

COVID-19 tracker: Russia's Sputnik V authorization delayed in EU; Delta variant cases 'rapidly increasing' in U.S.

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The European Union's approval for Russia's Sputnik V vaccine likely won't come until September at the earliest because of a missed June 10 deadline to submit data, sources tell Reuters. U.S. cases with the Delta variant first found in India are "rapidly increasing," a top health official warned. And more headlines.

BIO 2021: After COVID-19 showcased the power of science, J&J exec urges industry to start thinking 'cure' in cancer

By Eric Sagonowsky

Amid COVID-19 lockdowns, routine cancer screenings were put on the back burner. While that may be a short-term harm from the pandemic, the crisis also showed the world that science can solve tough problems, a Johnson & Johnson exec said, and that could bring long-term wins in oncology.

Molecular Partners prices $64M IPO, falling short of original goal

By Nick Paul Taylor

Molecular Partners has priced its IPO, setting it up to raise $63.8 million to fund work on oncology and infectious disease candidates. The IPO haul is set to fall well short of the original target after a five-day period in which the biotech’s share price in Switzerland fell 17%.

COVID-19 Tracker